Company:  SEAGEN INC. (SGEN)
Form Type:  8-K
Filing Date:  9/18/2020 
CIK:  0001060736 
Address:  21823 30TH DRIVE SE
SUITE
 
City, State, Zip:  BOTHELL, Washington 98021 
Telephone:  (425) 527-4000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$196.92  
Change: 
-3.74 (-1.86%)  
Trade Time: 
Oct 23  
Market Cap: 
$34.26B
Trade SGEN now with 

© 2020  
Description of Business
Seattle Genetics is a biotechnology company that develops and commercializes therapies targeting cancer. We are commercializing ADCETRIS®, or brentuximab vedotin, for the trbreatment of certain CD30-expressing lymphomas, and PADCEVTM, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers. We are also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Many of our programs, including ADCETRIS and PADCEV, are based on our antibody-drug conjugate, or ADC, technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. ADCETRIS is commercially available in more than 70 countries worldwide. We commercialize ADCETRIS in the U.S.
Register and access this filing in:     
  FORM 8-K
    SECTION 8 OTHER EVENTS
      Item 8.01. Other Events.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 Financial Statements and Exhibits.
    SIGNATURES
  EXHIBIT 99.1